Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• SETD2, a histone methyltransferase, is crucial in cellular processes.
• SETD2 is a therapeutic target in multiple myeloma with t(4;14) translocation.
• Previous work identified a SETD2 inhibitor tool compound for preclinical research.

Purpose of the Study:

• To evolve a lead compound into a clinically viable SETD2 inhibitor.
• To discover potent, selective, and orally bioavailable SETD2 inhibitors.
• To evaluate the pharmacokinetic and pharmacodynamic properties of novel SETD2 inhibitors.

Main Methods:

• Conformational design-driven lead optimization.
• Structure-based drug design.
• Preclinical evaluation in mouse xenograft models.

Main Results:

• Advanced chemistry leads were optimized for clinical evaluation.
• EZM0414 was discovered as a potent and selective SETD2 inhibitor.
• EZM0414 demonstrated good pharmacokinetics and pharmacodynamics in vivo.

Conclusions:

• EZM0414 is a promising clinical candidate for SETD2-targeted therapies.
• The optimized inhibitor exhibits favorable drug-like properties.
• This work validates SETD2 as a druggable target in multiple myeloma.